{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:29:06Z","timestamp":1761488946312},"reference-count":0,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[1994,10,1]],"date-time":"1994-10-01T00:00:00Z","timestamp":780969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1994,10]]},"abstract":"<jats:p>The activity of KRM-1648 was evaluated in a murine model of tuberculosis. Approximately 10(7) viable Mycobacterium tuberculosis ATCC 35801 organisms were given intravenously to 4-week-old female outbred mice. Treatment was started 1 week postinfection and given by gavage for 4 weeks. Viable-cell counts were determined from homogenates of spleen and lung tissues. The activity of KRM-1648 was compared with those of rifampin and rifabutin at 20 mg\/kg of body weight. KRM-1648 was more active than either rifampin or rifabutin against organisms in spleens and lungs. KRM-1648 alone and in combination with either isoniazid, ethambutol, pyrazinamide, or levofloxacin was evaluated. Other treatment groups received isoniazid, ethambutol, pyrazinamide, or levofloxacin as single agents. KRM-1648 was the most active single agent evaluated. KRM-1648-pyrazinamide and KRM-1648-isoniazid were the most active combinations. These combinations were more active than KRM-1648 alone. The promising activity of KRM-1648 in M. tuberculosis-infected mice suggests that it is a good candidate for clinical development as a new antituberculosis agent.<\/jats:p>","DOI":"10.1128\/aac.38.10.2245","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"2245-2248","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":40,"title":["Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model"],"prefix":"10.1128","volume":"38","author":[{"given":"S P","family":"Klemens","sequence":"first","affiliation":[{"name":"SUNY Health Science Center, Syracuse 13210."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Grossi","sequence":"additional","affiliation":[{"name":"SUNY Health Science Center, Syracuse 13210."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M H","family":"Cynamon","sequence":"additional","affiliation":[{"name":"SUNY Health Science Center, Syracuse 13210."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.38.10.2245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.38.10.2245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:35:23Z","timestamp":1645457723000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.38.10.2245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,10]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1994,10]]}},"alternative-id":["10.1128\/AAC.38.10.2245"],"URL":"https:\/\/doi.org\/10.1128\/aac.38.10.2245","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,10]]},"assertion":[{"value":"1994-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}